Azithromycin pulses in the treatment of inflammatory and pustular acne: Efficacy, tolerability and safety

Journal of Dermatological Treatment

Volumn 19, Issue 4, 2008, Pages 210-215

  Antonio, João Roberto ^a,e   Pegas, José Roberto ^b   Cestari, Tânia Ferreira ^c   Do Nascimento, Leninha Valéria ^d  

^a Center for Microorganism Investigation   (Brazil)

^b Padre Bento Hospital Complex   (Brazil)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^d STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^e NONE   (Brazil)

Author keywords

Azithromycin; Inflammatory acne

Indexed keywords

AZITHROMYCIN;

ABDOMINAL PAIN; ACNE VULGARIS; ADULT; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPIGASTRIC PAIN; FECES IMPACTION; FEMALE; HEADACHE; HUMAN; INCIDENCE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PATIENT MONITORING; PRIORITY JOURNAL; PUSTULE; SKIN INFLAMMATION; TASTE DISORDER; TREATMENT OUTCOME; VAGINITIS;

ACNE VULGARIS; ADOLESCENT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; COHORT STUDIES; FEMALE; HUMANS; MALE; PULSE THERAPY, DRUG; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 48249156926     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630701881506     Document Type: Article

References (25)

1. Webster GF. Acne vulgaris. BMJ. 2002;325:475-9.
2. Leyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol. 2003;49:S200-10.
3. Tan JK. Psychosocial impact of acne vulgaris: Evaluating the evidence. Skin Therapy Lett. 2004;9:1-3.
4. Farrar MD, Ingham E. Acne: Inflammation. Clin Dermatol. 2004;22:380-4.
5. Vowels BR, Yang S, Leyden JJ. Induction of proinflammatory cytokines by a soluble factor of Propionibacterium acnes: Implications for chronic inflammatory acne. Infect Immun. 1995;63:3158-65.
6. Leyden JJ. Current issues in antimicrobial therapy for the treatment of acne. J Eur Acad Dermatol Venereol. 2001;15(suppl 3):51-5.
7. Meynadier J, Alizerai M. Systemic antibiotics for acne. Dermatology. 1998;196:135-9.
8. Scheinfeld NS, Tutrone WD, Torres O, Weinberg JM. Macrolides in dermatology. Clin Dermatol. 2003;21:40-9.
9. Gammon WR, Meyer C, Lantis S, Shenefelt P, Reizner G, Cripps DJ. Comparative efficacy of oral erythromycin versus oral tetracycline in the treatment of acne vulgaris. A double-blind study. J Am Acad Dermatol. 1986;14:183-6.
10. Dunn CJ, Barradell LB. Azithromycin. A review of its pharmacological properties and use as 3-day therapy in respiratory tract infections. Drugs. 1996;51:483-505.
11. Voils SA, Evans ME, Lane MT, Schosser RH, Rapp RP. Use of macrolides and tetracyclines for chronic inflammatory diseases. Ann Pharmacother. 2005;39:86-94.
12. Pavone P. Azithromycin versus minociclina nel trattamento dell'acne volgare. Chron Derm. 1994;IV:867-73.
13. Gruber F, Grubisic-Greblo H, Kastelan M, Brajac I, Lenkovic M, Zamolo G. Azithromycin compared with minocycline in the treatment of acne comedonica and papulo-pustulosa. J Chemother. 1998;10:469-73.
14. Elewski BE. A novel treatment for acne vulgaris and rosacea. J Eur Acad Dermatol Venereol. 2000;14:423-4.
15. Fernandez-Obregon AC. Azithromycin for the treatment of acne. Int J Dermatol. 2000;39:45-50.
16. Parsad D, Pandhi R, Nagpal R, Negi KS. Azithromycin monthly pulse vs daily doxycycline in the treatment of acne vulgaris. J Dermatol. 2001;28:1-4.
17. Amin K, Riddle CC, Aires DJ, Schweiger ES. Common and alternate oral antibiotic therapies for acne vulgaris: A review. J Dermatol. 2007;8:873-80.
18. Kapadia N, Talib A. Acne treated successfully with azithromycin. Int J Dermatol. 2004;43:766-7.
19. Kus S, Yucelten D, Aytug A. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of acne vulgaris. Clin Exp Dermatol. 2005;30:215-20.
20. Rafie R, Yaghoobi R. Azithromicin versus tetracyclines in the treatment of acne vulgaris. J Dermatolog Treat. 2006;17:217-21.
21. Tan HH. Antibacterial therapy for acne: A guide to selection and use of systemic agents. AmJ Clin Dermatol. 2003;2:307-14.
22. Havlir DV, Dube MP, Sattler FR, Forthal DN, Kemper CA, Dunne MW, et al. Prophylaxis against disseminated mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med. 1996;335:392-8.
23. Hopkins S. Clinical toleration and safety of azithromycin. Am J Med. 1991;suppl 3A:40S-5S.
24. Steingrimsson O, Olafsson JH, Thorarinsson H, Ryan RW, Johnson RB, Tilton RC. Azithromycin in the treatment of sexually transmitted disease. J Antimicrob Chemother. 1990;25:109-14.
25. Schönwald S, Barsic B, Klinar I, Gunjaca M. Three-day azithromycin compared with ten-day roxythromycin treatment of atypical pneumonia. Scand J Infect Dis. 1994;26:706-10.